Retrospective analysis of zotarolimus-eluting stents (ZES) as compared to Endeavor ZES (E-ZES) on patients who underwent percutaneous coronary intervention (PCI)

Trial Profile

Retrospective analysis of zotarolimus-eluting stents (ZES) as compared to Endeavor ZES (E-ZES) on patients who underwent percutaneous coronary intervention (PCI)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2016

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Feb 2016 New trial record
    • 13 Dec 2015 Results published in the American Journal of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top